Rexahn Pharmaceuticals, Inc. (REXN)

[ED20332]

Brean Murray Analyst reiterates BUY rating for RNN PDF | Print | Written by M.E.Garza
Tuesday, 08 February 2011 10:09
1diggdiggDespite a Wall Street tabloid's efforts to misrepresent the facts from their own "sketchy" report to investors, a Wall Street Investment research firm who has been recommending Rexahn Pharmaceuticals, Inc (AMEX: RNN ) to various funds and institutional clients has re-iterated a BUY rating this morning.



Ling Wang, CFA at Brean Murray, Carret & Co., feels that Detailed Phase 2a data for Serdaxin does show promising preliminary efficacy in severe
depression patients - Rexahan recently presented concept trial evaluating its leading CNS compound Serdaxin of Neuropsychopharmacologists (ACNP) Annual Meeting (data slides were posted on the company’s website). In this multi-center, randomized, double parallel group trial, Serdaxin achieved mean % reduction in MADRS score of 46.0%, 37.9% and 41.4% for 5, 10 and 15 mg Serdaxin, respectively, compared to 43.1% of the placebo patients (Exhibit 1A).

Brean Murray, Carret & Co., LLC follows are emerging growth companies whose securities typically involve a higher degree of risk and more volatility than the securities of more established companies.

They join BioMedReports, Motley Fool, Louis Navellier (whose report also appears at TheStreet.Com) and other analysts who believe RNN is set to continue higher.

Our full report about Rexahn Pharmaceuticals, Inc (AMEX: RNN) is set to be published in this space later today. In the meantime, readers can access the newly published Brean Murray analysis here: http://alturl.com/4vaia




Disclosure: Long RNN



Read the full report: http://biomedreports.com/2011020863438/breen-murray-reiterates-buy-rating-for-rnn.html#ixzz1DNoo5g6z